tradingkey.logo

Icecure Medical Ltd

ICCM
查看详细走势图
0.590USD
+0.039+7.04%
收盘 02/06, 16:00美东报价延迟15分钟
40.69M总市值
亏损市盈率 TTM

Icecure Medical Ltd

0.590
+0.039+7.04%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+7.04%

5天

-3.45%

1月

-11.48%

6月

-34.37%

今年开始到现在

-3.29%

1年

-54.26%

查看详细走势图

TradingKey Icecure Medical Ltd股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Icecure Medical Ltd当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在医疗设备与耗材行业排名101/205位。机构持股占比很高,近一月多位分析师给出公司评级为买入。最高目标价3.12。中期看,股价处于下降通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Icecure Medical Ltd评分

相关信息

行业排名
101 / 205
全市场排名
272 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Icecure Medical Ltd亮点

亮点风险
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
业绩增长期
公司处于发展阶段,最新年度总收入3.29M美元
估值高估
公司最新PE估值-2.28,处于3年历史高位
机构加仓
最新机构持股443.26K股,环比增加16.29%
肯·费雪持仓
明星投资者肯·费雪持仓,最新持仓市值0.00
活跃度增加
近期活跃度增加,过去20天平均换手率0.36

分析师目标

根据 2 位分析师
买入
评级
3.125
目标均价
+466.94%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Icecure Medical Ltd新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Icecure Medical Ltd简介

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
公司代码ICCM
公司Icecure Medical Ltd
CEOShamir (Eyal)
网址https://icecure-medical.com/
KeyAI